Thrivent Financial for Lutherans
INSY

Thrivent Financial for Lutherans’s Insys Therapeutics, Inc. INSY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100,670
Closed -$1.06M – 2104
2017
Q1 		$1.06M Buy
+100,670
New +$1.07M ﹤0.01% 1129

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Thrivent Financial for Lutherans's INSY Position: Q2 2017 in Review

Thrivent Financial for Lutherans sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 100,670 shares — an estimated $1.06M sold.

Thrivent Financial for Lutherans first reported a position in INSY in Q1 2017 and held it in 1 quarter. The position peaked at $1.06M in Q1 2017. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • Thrivent Financial for Lutherans reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 100,670 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $1.06M.
  • Thrivent Financial for Lutherans first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Insys Therapeutics, Inc. position peaked at $1.06M in Q1 2017.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2017, filed 11 Aug 2017.